Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Halozyme (HALO)

Halozyme Raises 2026 Revenue Guidance to $1,710 Million-$1,810 Million

Positive Impact 4 of 5 guidance Written later

Halozyme raised its 2026 financial guidance on January 28, 2026, with total revenue now expected at $1,710 million to $1,810 million, up from $1,430 million to $1,530 million. The company also gave preliminary, unaudited 2025 total revenue of $1,385 million to $1,400 million and disclosed its acquisition of Surf Bio, which carries up to $400 million in total consideration.

Key points

  • 2026 royalty revenue guidance raised to $1,130 million-$1,170 million from $900 million-$940 million
  • 2026 non-GAAP diluted EPS guidance raised to $7.75-$8.25 from $6.50-$7.00, including about $60 million of Hypercon and Surf Bio investment not in prior guidance
  • Surf Bio acquired for an upfront payment of $300 million, plus up to $100 million in milestone payments
  • Preliminary 2025 royalty revenue estimated at $865 million-$870 million, with 51% to 52% year-over-year growth

The filing

CompanyHalozyme (HALO)
Form8-K, current report
Filed with the SECJan 28, 2026, 6:40 AM ET
Accession number0001159036-26-000011

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:12 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.